STOCK TITAN

[Form 4] HEALTHEQUITY, INC. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Michael Henry Fiore, EVP and Chief Commercial Officer at HealthEquity, Inc. (HQY), reported sales of a total of 3,430 shares of common stock across two transactions on 10/06/2025 and 10/07/2025. The first sale of 1,649 shares on 10/06/2025 reported a price of $88.5674 and the second sale of 1,781 shares on 10/07/2025 reported a price of $88.21. Following these disposals, Mr. Fiore beneficially owns 49,795 shares directly. The filing states the trades were made under a Rule 10b5-1 trading plan adopted on 12/18/2024, and the Form 4 was signed by an attorney-in-fact on 10/08/2025.

Michael Henry Fiore, EVP e Chief Commercial Officer di HealthEquity, Inc. (HQY), ha riportato vendite totali di 3.430 azioni ordinarie attraverso due operazioni in data 10/06/2025 e 10/07/2025. La prima vendita di 1.649 azioni in data 10/06/2025 ha riportato un prezzo di $88.5674 e la seconda vendita di 1.781 azioni in data 10/07/2025 ha riportato un prezzo di $88.21. Dopo tali disposizioni, il signor Fiore detiene direttamente 49.795 azioni. Il deposito dichiara che le operazioni sono consistite in un piano di trading Rule 10b5-1 adottato in data 12/18/2024, e il Modulo 4 è stato firmato da un attorney-in-fact in data 10/08/2025.

Michael Henry Fiore, vicepresidente ejecutivo y director comercial de HealthEquity, Inc. (HQY), reportó ventas por un total de 3,430 acciones ordinarias a través de dos transacciones en las fechas 10/06/2025 y 10/07/2025. La primera venta de 1,649 acciones en 10/06/2025 informó un precio de $88.5674 y la segunda venta de 1,781 acciones en 10/07/2025 informó un precio de $88.21. Tras estas disposiciones, el Sr. Fiore posee beneficiosamente 49,795 acciones directamente. El archivo indica que las operaciones se realizaron bajo un plan de trading Rule 10b5-1 adoptado el 12/18/2024, y el Formulario 4 fue firmado por un apoderado en 10/08/2025.

마이클 헨리 피오레, HealthEquity, Inc. (HQY)에서 EVP 겸 최고 상업 책임자로, 3,430주의 일반주를 두 건의 거래로 2025-10-062025-10-07에 매도했다고 보고했습니다. 첫 매도는 1,649주를 2025-10-06에 매도했고 가격은 $88.5674이며 두 번째 매도는 1,781주를 2025-10-07에 매도했고 가격은 $88.21입니다. 이러한 처분 후, Fiore 씨는 직접적으로 49,795주를 보유하게 됩니다. 제출서에 따르면 거래는 10b5-1 규칙의 거래 계획에 따라 수행되었으며, 채무 대행자가 2025-10-08에 서명한 Form 4입니다.

Michael Henry Fiore, vice-président exécutif et directeur commercial chez HealthEquity, Inc. (HQY), a déclaré des ventes d'un total de 3 430 actions ordinaires réparties sur deux opérations les dates 10/06/2025 et 10/07/2025. La première vente de 1 649 actions le 10/06/2025 a affiché un prix de $88.5674 et la deuxième vente de 1 781 actions le 10/07/2025 a affiché un prix de $88.21. Suite à ces dispositions, M. Fiore détient directement 49 795 actions. Le dépôt indique que les transactions ont été effectuées dans le cadre d'un plan de trading Rule 10b5-1 adopté le 12/18/2024, et le Formulaire 4 a été signé par un mandataire le 10/08/2025.

Michael Henry Fiore, EVP und Chief Commercial Officer bei HealthEquity, Inc. (HQY), meldete Verkäufe insgesamt von 3.430 Stammaktien in zwei Transaktionen am 10/06/2025 und 10/07/2025. Der erste Verkauf von 1.649 Aktien am 10/06/2025 meldete einen Preis von $88.5674 und der zweite Verkauf von 1.781 Aktien am 10/07/2025 meldete einen Preis von $88.21. Nach diesen Veräußerungen besitzt Herr Fiore direkt advantageous 49.795 Aktien. Die Einreichung gibt an, dass die Geschäfte unter einem Rule 10b5-1-Handelsplan vorgenommen wurden, der am 12/18/2024 angenommen wurde, und das Formular 4 wurde von einem Bevollmächtigten am 10/08/2025 unterzeichnet.

مايكل هنري فيور، نائب رئيس تنفيذي ومدير التجارة لدى HealthEquity, Inc. (HQY)، أفاد ببيع إجمالي قدره 3,430 سهمًا عاديًا من خلال صفقتين في تاريخ 10/06/2025 و 10/07/2025. البيع الأول ل 1,649 سهمًا في 10/06/2025 أظهر سعرًا قدره $88.5674 والبيع الثاني ل 1,781 سهمًا في 10/07/2025 أظهر سعرًا قدره $88.21. بعد هذه التصرفات، يمتلك السيد فيور مباشرةً 49,795 سهمًا. يشير الملف إلى أن التداولات تمت بموجب خطة تداول من القاعدة 10b5-1 التي اعتمدت في 12/18/2024، وأن النموذج 4 تم توقيعه بواسطة محامٍ وكيل في 10/08/2025.

迈克尔·亨利·菲奥雷,HealthEquity, Inc. (HQY) 的执行副总裁兼首席商务官,报告在 2025-10-062025-10-07 两笔交易中共出售了 3,430 股普通股。第一笔在 2025-10-06 的出售为 1,649 股,价格为 $88.5674;第二笔在 2025-10-07 的出售为 1,781 股,价格为 $88.21。完成这些处置后,Fiore 先生直接持有 49,795 股。提交文件称交易是在 10b5-1 规则的交易计划下进行,该计划于 2024-12-18 通过,且 Form 4 由代理律师在 2025-10-08 签署。

Positive
  • Trades executed under a Rule 10b5-1 plan, showing preplanned disposition (adopted 12/18/2024)
  • Complete disclosure via Form 4 with transaction details and post-sale ownership of 49,795 shares
Negative
  • Insider reduction of holdings by 3,430 shares on 10/06/202510/07/2025
  • Sales executed at ~$88.3 per share, lowering direct beneficial stake

Insights

Insider sales were pre-planned under a 10b5-1 plan and reduced direct holdings to 49,795 shares.

The reported sales of 3,430 shares occurred in two transactions on 10/06/2025 and 10/07/2025

The presence of a Rule 10b5-1 plan (adopted 12/18/2024) indicates the trades were executed under an affirmative-defense schedule; investors should note the plan timing and continued ownership level of 49,795 shares as the immediate post-trade position. Monitor periodic Form 4 filings for any further planned or unplanned changes in holdings within the next few reporting cycles.

Michael Henry Fiore, EVP e Chief Commercial Officer di HealthEquity, Inc. (HQY), ha riportato vendite totali di 3.430 azioni ordinarie attraverso due operazioni in data 10/06/2025 e 10/07/2025. La prima vendita di 1.649 azioni in data 10/06/2025 ha riportato un prezzo di $88.5674 e la seconda vendita di 1.781 azioni in data 10/07/2025 ha riportato un prezzo di $88.21. Dopo tali disposizioni, il signor Fiore detiene direttamente 49.795 azioni. Il deposito dichiara che le operazioni sono consistite in un piano di trading Rule 10b5-1 adottato in data 12/18/2024, e il Modulo 4 è stato firmato da un attorney-in-fact in data 10/08/2025.

Michael Henry Fiore, vicepresidente ejecutivo y director comercial de HealthEquity, Inc. (HQY), reportó ventas por un total de 3,430 acciones ordinarias a través de dos transacciones en las fechas 10/06/2025 y 10/07/2025. La primera venta de 1,649 acciones en 10/06/2025 informó un precio de $88.5674 y la segunda venta de 1,781 acciones en 10/07/2025 informó un precio de $88.21. Tras estas disposiciones, el Sr. Fiore posee beneficiosamente 49,795 acciones directamente. El archivo indica que las operaciones se realizaron bajo un plan de trading Rule 10b5-1 adoptado el 12/18/2024, y el Formulario 4 fue firmado por un apoderado en 10/08/2025.

마이클 헨리 피오레, HealthEquity, Inc. (HQY)에서 EVP 겸 최고 상업 책임자로, 3,430주의 일반주를 두 건의 거래로 2025-10-062025-10-07에 매도했다고 보고했습니다. 첫 매도는 1,649주를 2025-10-06에 매도했고 가격은 $88.5674이며 두 번째 매도는 1,781주를 2025-10-07에 매도했고 가격은 $88.21입니다. 이러한 처분 후, Fiore 씨는 직접적으로 49,795주를 보유하게 됩니다. 제출서에 따르면 거래는 10b5-1 규칙의 거래 계획에 따라 수행되었으며, 채무 대행자가 2025-10-08에 서명한 Form 4입니다.

Michael Henry Fiore, vice-président exécutif et directeur commercial chez HealthEquity, Inc. (HQY), a déclaré des ventes d'un total de 3 430 actions ordinaires réparties sur deux opérations les dates 10/06/2025 et 10/07/2025. La première vente de 1 649 actions le 10/06/2025 a affiché un prix de $88.5674 et la deuxième vente de 1 781 actions le 10/07/2025 a affiché un prix de $88.21. Suite à ces dispositions, M. Fiore détient directement 49 795 actions. Le dépôt indique que les transactions ont été effectuées dans le cadre d'un plan de trading Rule 10b5-1 adopté le 12/18/2024, et le Formulaire 4 a été signé par un mandataire le 10/08/2025.

Michael Henry Fiore, EVP und Chief Commercial Officer bei HealthEquity, Inc. (HQY), meldete Verkäufe insgesamt von 3.430 Stammaktien in zwei Transaktionen am 10/06/2025 und 10/07/2025. Der erste Verkauf von 1.649 Aktien am 10/06/2025 meldete einen Preis von $88.5674 und der zweite Verkauf von 1.781 Aktien am 10/07/2025 meldete einen Preis von $88.21. Nach diesen Veräußerungen besitzt Herr Fiore direkt advantageous 49.795 Aktien. Die Einreichung gibt an, dass die Geschäfte unter einem Rule 10b5-1-Handelsplan vorgenommen wurden, der am 12/18/2024 angenommen wurde, und das Formular 4 wurde von einem Bevollmächtigten am 10/08/2025 unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Fiore Michael Henry

(Last) (First) (Middle)
C/O HEALTHEQUITY, INC.
15 W. SCENIC POINTE DR., STE. 100

(Street)
DRAPER UT 84020

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
HEALTHEQUITY, INC. [ HQY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, CHIEF COMMERCIAL OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
10/06/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/06/2025 F 1,649 D $88.5674 51,576 D
Common Stock 10/07/2025 S(1) 1,781 D $88.21 49,795 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2024.
Remarks:
The Power of Attorney given by Mr. Fiore was previously filed with the U.S. Securities and Exchange Commission on March 29,2024, as an exhibit to a statement on Form 3 filed by Mr. Fiore with respect to HealthEquity, Inc. and is hereby incorporated by reference.
/s/ Michael Newton, Attorney-in-Fact 10/08/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did HealthEquity (HQY) insider Michael Fiore report on Form 4?

He reported sales of 3,430 common shares across two transactions, reducing his direct ownership to 49,795 shares.

Were the sales by Michael Fiore part of a trading plan?

Yes, the filing states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on 12/18/2024.

What prices were the HQY shares sold at?

The Form 4 reports prices of $88.5674 on 10/06/2025 and $88.21 on 10/07/2025.

How many shares did Mr. Fiore own after the reported transactions?

Following the reported transactions he beneficially owned 49,795 shares of common stock.

When was the Form 4 signed and filed?

The signature on the Form 4 is dated 10/08/2025 and indicates filing compliance for these transactions.
Healthequity Inc

NASDAQ:HQY

HQY Rankings

HQY Latest News

HQY Latest SEC Filings

HQY Stock Data

7.99B
84.31M
2.21%
108.47%
5.82%
Health Information Services
Services-business Services, Nec
Link
United States
DRAPER